# A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

> **NCT04833582** · PHASE1 · COMPLETED · sponsor: **K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc** · enrollment: 31 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Azenosertib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04833582
- **Lead sponsor:** K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2023-08-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833582, "A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04833582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*